An economic model to value companion diagnostics in non-small-cell lung cancer

By Lieberthal Robert D   Dudash Kellie   Axelrod Rita   Goldfarb Neil I  

Personalized Medicine, Vol. 10, Iss. 2, 2013-03 ,pp. : 139-147

Future Medicine

Access to resources Recommend Favorite

The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer

By Suzuki Takeshi   Mitsudomi Tetsuya   Hida Toyoaki  

Personalized Medicine, Vol. 1, Iss. 1, 2004-12 ,pp. : 27-34

Future Medicine

Access to resources Recommend Favorite

The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer

By Akerley Wallace L.   Nelson Richard E.   Cowie Robin H.   Spinella Dominic G.   Hornberger John  

Current Medical Research and Opinion, Vol. 29, Iss. 5, 2013-05 ,pp. : 517-525

Informa Healthcare

Access to resources Recommend Favorite

A review of the benefit–risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer

By Park Keunchil   Goto Koichi  

Current Medical Research and Opinion, Vol. 22, Iss. 3, 2006-03 ,pp. : 561-573

Informa Healthcare

Access to resources Recommend Favorite

Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 509-513

Karger

Access to resources Recommend Favorite